Regenerative medicine

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to...

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.

Regenerative medicine holds the promise of regenerating damaged tissues and organs in the body by replacing damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues or organs.

Regenerative medicine also empowers scientists to grow tissues and organs in the laboratory and safely implant them when the body cannot heal itself.

Regenerative medicine has the potential to solve the problem of the shortage of organs available for donation compared to the number of patients that require life-saving organ transplantation.

Depending on the source of cells, it can potentially solve the problem of organ transplant rejection if the organ's cells are derived from the patient's own tissue or cells.

Regenerative medicine deal making

Regenerative medicine is seeing more interest in terms of deal making, with an increase in the number of partnering opportunities, deals and dealmaker amongst the top pharma, top biotech, pharmaceutical and biotechnology companies.

Report: Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Example deal:

Distribution agreement for Omega3 tissue regeneration technology

1 February 2013

Kerecis, Medline Industries

Kerecis announced the signing of a distribution agreement with Medline Industries.

Kerecis is a medical device company focused on the treatment of tissue damage with Omega3-based regenerative technologies.

The contract with Medline represents the first commercialization of the company's technology.

MariGen Omega3 is a fish skin that has had all its cells and antigenic materials removed, leaving behind an extra-cellular matrix that looks like fish skin, and contains Omega3 and other fish-skin components.

Under the terms of the agreement, Medline will sell products that utilize the MariGen Omega3 regenerative technology for the management of chronic wounds, including diabetic, vascular and other hard-to-heal wounds.

Initially Medline will sell products based on the MariGen Omega3 technology in the United Kingdom and several Middle Eastern countries.

For full details: subscribe to Current Agreements for full details of this deal, all [glossary term] deals, and partnering, M&A and financing deals in the life science industry

Report: Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Read: more on regenerative medicine deals in pharma, biotech, life science partnering deal news, insights and glossary

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email